睿智医药董事长胡瑞连：深耕创新药智造 打造医药CXO服务新标杆

Group 1 - The pharmaceutical research outsourcing industry is entering a new development stage with the integration of innovative drug development and AI technology [1] - The company has been focusing on innovation in the CXO (Contract Research and Manufacturing Outsourcing) field since the new CEO took over [1] - The company has established a comprehensive service system covering target discovery, process development, preclinical research, commercial production, and global submission [1] Group 2 - The business scope has expanded to include new modality drugs such as ADC/XDC (antibody-drug conjugates), small nucleic acids, and peptides, as well as chemical and biological drugs [1] - The company has formed a global research and production service network [1]